Tag Archives: bioscience

This week’s media picks: infrastructure, Bangladesh safety, fracking, climate change, bioscience

FT (23/4/14): Leading article: Time to invest in Britain’s future

As the Prime Minister, David Cameron, and Chancellor, George Osborne, welcomed £36 billion investment in infrastructure projects, the Financial Times, remained to be impressed. In a leader, it said that one of the biggest and most persistent questions facing the UK economy is the worryingly low level of investment in infrastructure. Despite fine words, the government’s record is decidedly mixed, and the new set of initiatives may not match the scale needed to raise infrastructure spending to the level required. The FT outlines three areas of weakness in policy: 1) Spending is not high enough, and is persistently less than many of our competitors; 2) Given low interest rates, the government should borrow more to finance big projects; and 3) the government needs to establish a more stable and clearer framework for private sector investment.

Fibre2Fashion (24/4/14) Bangladesh Safety Accord on course, says UNI official

A year after the tragic collapse of the Rana Plaza factory building in Bangladesh, a demonstration of corporate social responsibility in action, rather than just words, is making progress towards improving the safety, prospects and lives of the country’s garment workers. Despite the many barriers to progress imposed by the political, social and commercial cultures of Bangladesh, the Accord on Fire and Building Safety in Bangladesh can be proud of its progress when it marks its own one year anniversary next month.

An official from, UNI Global, one of the two global union bodies that negotiated the Bangladesh Accord, Alke Boessiger, said: “The inspection program is in full operation. There is a strong team of more than more than 100 technical experts and engineers in Bangladesh who are conducting 45 inspections per week, with the aim to inspect 1500 factories by October.  More than 280 factories have been inspected for fire and electrical issues and 240 for structural safety.  Every inspection has revealed critical issues which must be repaired as a condition of doing business with signatory brands in the future. These issues include, for example, the absence of fire doors to separate the work area from the fire exit.  Brands are responsible to ensure that sufficient financial resources are available for the renovations and improvements.”

FT (24/4/14): Shale gas a multi-billion-pound opportunity for UK business

A report by EY, commissioned by the UKOOG, the shale-gas trade body, said that fracking shale gas could potentially generate 64,000 jobs in the oil and gas supply chain. It said that over the next 15 years, the UK would need to invest £17 billion on specialised fracking equipment and skills. This won’t mollify fracking’s opponents, but does at least show that the industry is seeking to make a positive, factually-based case for its development.

The Guardian (25/4/14): Kingfisher CEO warns on underestimating impact of climate change on business

In an opinion piece, Kingfisher plc CEO, Ian Cheshire urged business to sign a communiqué aimed at policymakers gathering in Paris next year for the UN Climate Change Conference. He warned that resource scarcity, energy price increases and extreme weather are real and growing threats to the long-term viability of business. That’s why hesigned the Trillion Tonne Communique, drawn up by the Prince of Wales’ Corporate Leaders Group, and is encouraging other business leaders to do so too. Adverse climate events are increasing costs for business, Kingfisher’s alone, were tens of millions of pounds, and as business doesn’t have a seat at the table, it needs more of them to sign the Trillion Tonne Communique to ensure that its voice is heard. 103 businesses world wide have signed so far, but it will require quite a few more to overcome the political resistance that clearly exists in some quarters.

FT (25/4/14): UK medical science drive shaken by US takeover fears

News that AstraZeneca was approached by Pfizer about a £60 billion takeover, has called into question the UK’s ambition to remain a leading global player in life sciences. AstraZeneca and GlaxoSmithKline are the only large companies with research and development operations in the UK. Oxford University’s Professor John Bell said: “If we were to lose one of them it would be a real blow to our capabilities. It’s a sector that is crucial to our future economic success. The news prompted Andrew Miller MP, Chairman of the House of Commons science committee to call for tougher standards to protect strategic UK assets, such as considering the national interest when looking at takeovers. Steve Bates, chief executive of the UK Bioindustry Association, pointed to successful smaller biotech companies, but said: “It is important to have whales in the ecosystems around which minnows can flourish.”

Advertisements